The Rescue: Moving RA Patients from Adalimumab to Baricitinib

The long-term extension study revealed patients who switched from adalimumab to baricitinib showed improvements in disease control through 12 weeks, and patients on baricitinib maintained improvements in physical function and pain. The most common treatment-emergent adverse events were infections and gastrointestinal disorders.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

Tanaka Y, Fautrel B, Keystone EC, et al. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: Phase 3 data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019 Jul;78(7):890–898.

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

New research shows that baricitinib is a safe and effective RA treatment. The medication has also been approved for use in Japan and is recommended for use in the U.K…

Recent clinical trials have shown that baricitinib is safe and effective for treating patients with rheumatoid arthritis who have proved non-responsive to multiple biologic treatments…

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

New Insights & Approvals for Baricitinib

Baricitinib Has Promising Clinical Trial Results for Treating RA

Related Articles